Exploring treatment options for hepatocellular carcinoma
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study in Guangxi, China (GUIDANCE)
This study is testing different treatment combinations for liver cancer to see which ones work best and help patients live longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Guangxi Medical University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Nanning, China) |
| Trial ID | NCT06405321 on ClinicalTrials.gov |
What this trial studies
This multicenter retrospective study focuses on patients with hepatocellular carcinoma (HCC) who have received conversion or neoadjuvant therapy. The research aims to establish a comprehensive database from Guangxi province, China, to analyze the effectiveness and safety of various treatment combinations, including transarterial chemoembolization and targeted therapies. By evaluating patient outcomes, the study seeks to identify the most beneficial treatment strategies and follow-up options for HCC patients. The ultimate goal is to provide evidence supporting the use of conversion or neoadjuvant therapy in improving patient survival rates.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically or clinically confirmed HCC who have received conversion or neoadjuvant therapy as their initial treatment.
Not a fit: Patients with concurrent malignancies, incomplete medical data, or follow-up times less than three months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify optimal treatment strategies that improve survival outcomes for patients with hepatocellular carcinoma.
How similar studies have performed: While there have been studies on HCC treatments, the specific focus on conversion or neoadjuvant therapy in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or clinically confirmed diagnosis of HCC. * Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy. * Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1. * With Child-Pugh 5\~7 scores. Exclusion Criteria: * Concurrent with other malignancies within 5 years. * Incomplete medical data. * Follow-up time less than 3 months.
Where this trial is running
Nanning, China
- Jian-Hong Zhong — Nanning, China, China (Recruiting)
Study contacts
- Principal investigator: Jian-Hong Zhong, Ph.D — Guangxi Medical University Cancer Hospital
- Study coordinator: Jian-Hong Zhong, Ph.D
- Email: zhongjianhong66@163.com
- Phone: +86 771 5301253
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.